Active substances
Ezetimibe + Simvastatin
- SFDA 9
- US FDA 10
- US price lines 6
- NHS prices 3
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| INEGY | 20,10 mg,mg | Tablet · Oral use | 28 Blister | SAR 119.40 | NCE · Prescription | Organon Pharma UK Limited | Valid |
| INEGY | 40,10 mg,mg | Tablet · Oral use | 28 Blister | SAR 135.75 | NCE · Prescription | Organon Pharma UK Limited | Valid |
| LUNIA | 10,40 mg,mg | Tablet · Oral use | 28 Blister | SAR 156.55 | Generic · Prescription | ALPHA PHARMA INDUSTRY | Valid |
| LUNIA | 10,20 mg,mg | Tablet · Oral use | 28 Blister | SAR 134.20 | Generic · Prescription | ALPHA PHARMA INDUSTRY | Valid |
| Simvagen Plus | 10,20 mg,mg | Tablet · Oral use | 30 Blister | SAR 133.50 | Generic · Prescription | RIYADH PHARMA | Valid |
| Simvagen Plus | 10,40 mg,mg | Tablet · Oral use | 30 Blister | SAR 155.75 | Generic · Prescription | RIYADH PHARMA | Valid |
| INEGY 20-10MG TABLETS | 20, 10 mg | Tablet · Oral use | 28 Blister | SAR 273.40 | NCE · Prescription | MERCK SHARP & DOHME | Withdrawn by MAH · Not Marketed |
| INEGY 40-10MG TABLET | 40, 10 mg | Tablet · Oral use | 28 Blister | SAR 296.70 | NCE · Prescription | MERCK SHARP & DOHME | Withdrawn by MAH · Not Marketed |
| INEGY 80-10MG TABLETS | 80, 10 mg | Tablet · Oral use | 28 Blister | SAR 251.70 | NCE · Prescription | MERCK SHARP & DOHME | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
CORONARY ARTERY DISEASE; DYSLIPIDEMIA
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| VYTORIN | 10MG;10MG; 10MG;20MG; 10MG;40MG; 10MG;80MG | tablet · oral | ORGANON | Prescription | 23 Jul 2004 |
| EZETIMIBE AND SIMVASTATIN | 10MG;10MG; 10MG;20MG; 10MG;40MG; 10MG;80MG | tablet · oral | DR REDDYS LABS SA | Prescription | 26 Apr 2017 |
| EZETIMIBE AND SIMVASTATIN | 10MG;10MG; 10MG;20MG; 10MG;40MG; 10MG;80MG | tablet · oral | ALKEM LABS LTD | Prescription | 22 Dec 2017 |
| EZETIMIBE AND SIMVASTATIN | 10MG;10MG; 10MG;20MG; 10MG;40MG; 10MG;80MG | tablet · oral | GLENMARK PHARMS LTD | Prescription | 27 Jun 2019 |
| EZETIMIBE AND SIMVASTATIN | 10MG;10MG; 10MG;20MG; 10MG;40MG; 10MG;80MG | tablet · oral | AUROBINDO PHARMA USA | Prescription | 17 Dec 2020 |
| EZETIMIBE AND SIMVASTATIN | 10MG;10MG; 10MG;20MG; 10MG;40MG; 10MG;80MG | tablet · oral | ANI PHARMS | Discontinued | 26 Apr 2017 |
| EZETIMIBE AND SIMVASTATIN | 10MG;10MG; 10MG;20MG; 10MG;40MG; 10MG;80MG | tablet · oral | WATSON LABS INC | Discontinued | 26 Apr 2017 |
| EZETIMIBE AND SIMVASTATIN | 10MG;10MG; 10MG;20MG; 10MG;40MG; 10MG;80MG | tablet · oral | AMNEAL PHARMS CO | Discontinued | 21 Nov 2017 |
| EZETIMIBE AND SIMVASTATIN | 10MG;10MG; 10MG;20MG; 10MG;40MG; 10MG;80MG | tablet · oral | SCIEGEN PHARMS | Discontinued | 10 Dec 2024 |
| EZETIMIBE AND SIMVASTATIN | 10MG;10MG; 10MG;20MG; 10MG;40MG; 10MG;80MG | tablet · oral | TORRENT | Discontinued | 27 Jan 2025 |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | EZETIMIBE-SIMVASTATIN 10-10 MG | $0.27376 | per EA | 23 Sep 2026 |
| US NADAC | EZETIMIBE-SIMVASTATIN 10-20 MG | $0.1985 | per EA | 23 Sep 2026 |
| US NADAC | EZETIMIBE-SIMVASTATIN 10-40 MG | $0.18305 | per EA | 23 Sep 2026 |
| US NADAC | EZETIMIBE-SIMVASTATIN 10-80 MG | $0.28477 | per EA | 23 Sep 2026 |
| US NADAC | VYTORIN 10-20 MG TABLET | $13.6206 | per EA | 23 Sep 2026 |
| US NADAC | VYTORIN 10-40 MG TABLET | $13.79507 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Simvastatin 20mg / Ezetimibe 10mg tablets | £33.42 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Simvastatin 40mg / Ezetimibe 10mg tablets | £38.98 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Simvastatin 80mg / Ezetimibe 10mg tablets | £41.21 | 28 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Components
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.